Congress moved forward with its efforts to address drug shortages, drug pricing, pharmacy benefit managers (PBMs), and transparency ahead of the August recess. This policy post covers the discussion draft of the Stop Drug Shortages Act, the Lowering Drug Costs for American Families Act (H.R. 4895), the Modernizing and Ensuring PBM Accountability (MEPA) Act, the Health Care Price Transparency Act of 2023 (H.R. 4822), and the Providers and Payers COMPETE Act (H.R. 3284).
Congress is now on recess until the Senate reconvenes on September 5th and the House reconvenes on September 11th.
Also, read to the end for a brief update on CBSA’s engagement with Prescription Drug Affordability Board (PDAB) implementation work.
Drug Shortages
On July 28th, the House Energy & Commerce Committee Chair Cathy McMorris-Rodgers (R-WA) unveiled a discussion draft with policy proposals…
Click here to view original post
